Thilo Schroeder

Partner at Nextech Invest AG

Thilo Schroeder

Thilo Schroeder

Partner at Nextech Invest AG

Overview
RelSci Relationships

134

Number of Boards

5

Birthday

1982

Age

36

Relationships
RelSci Relationships are individuals Thilo Schroeder likely has professional access to. A relationship does not necessarily indicate a personal connection.

Co-Founder at ImaginAb, Inc.

Relationship likelihood: Strong

Senior Advisor to the President for Experimental Therapeutics at Dana-Farber Cancer Institute, Inc.

Relationship likelihood: Strong

Partner at The Column Group LLC

Relationship likelihood: Strong

Founder & Director at Peloton Therapeutics, Inc.

Relationship likelihood: Strong

Professor & Chairman-Biochemistry Department at The University of Texas - Southwestern Medical Center

Relationship likelihood: Strong

Chief Executive Officer at ImaginAb, Inc.

Relationship likelihood: Strong

Chief Executive Officer at Peloton Therapeutics, Inc.

Relationship likelihood: Strong

Partner at Third Rock Ventures LLC

Relationship likelihood: Strong

Partner at Topspin Management LLC

Relationship likelihood: Strong

Founder at The Column Group LLC

Relationship likelihood: Strong

Paths to Thilo Schroeder
Potential Connections via
Relationship Science
You
Thilo Schroeder
Partner at Nextech Invest AG
Education
Ph.D. Biochemistry

The University of Zurich, located in the city of Zürich, is the largest university in Switzerland.

Technische Universität Darmstadt, commonly referred to as TU Darmstadt is a research university in the city of Darmstadt

Career History
Partner
2012 - Current

Nextech is an active manager which invests in selected life science companies in Europe, Asia and the US. They have a particular focus on cancer therapy. They help build successful business ventures from life science innovations originating in academia and industry and also support the incubation of strong research teams.The firm seeks to invest in well managed companies with proprietary, cutting-edge products which understand the market and their competitors. Their investment approach aims to take drug assets in the preclinical stage and build their value by demonstrating clinical efficacy.Nextech mainly acts as lead investor in Europe and co-invests in OECD countries outside of Europe. They make investments based on recommendations from their Scientific Advisory Board, which assesses the scientific concept and the drug development plan.The firm aims to exit their investments through trade sales and IPOs after demonstrating efficacy or comparable benefits in human studies.

Professional
Prior

Amgen discovers, develops, manufactures, and delivers innovative human therapeutics. A leader in biotechnology since 1980, Amgen was one of the first companies to realise the new science’s promise by bringing safe, effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease, and other serious illnesses. Amgen pioneered the development of novel products based on advances in recombinant DNA and molecular biology, and launched the biotechnology industry’s first blockbuster medicines. Today, as a Fortune 500 company serving millions of patients, Amgen continues to be an entrepreneurial, science-driven enterprise dedicated to helping people fight serious illness.

Boards & Committees
Member, Board of Directors
2018 - Current

Revolution Medicines, Inc develops new therapies derived from natural products. It develops therapies that harness the complex chemicals of life by reconfiguring natural substances into best-in-class medicines. The company was founded by Martin D. Burke and David L. Pompliano and Michael Fischbach in February 2015 and is headquartered in Redwood City, CA.

Director
2018 - Current

IDEAYA Biosciences, Inc. develops cancer therapeutics. It is an oncology-focused biotechnology company committed to the discovery of personalized synthetic lethality medicines targeting DNA damage and repair for genetically defined patient populations and immuno-oncology therapies targeting the tumor microenvironment. The company was founded by Yujiro S. Hata and Jeffrey Hager in 2015 and is headquartered in South San Francisco, CA.

Member, Board of Directors
Current

ImaginAb, Inc. develops engineered antibody fragments for diagnostic imaging and novel therapeutic applications. It products offer actionable data to facilitate diagnosis of disease, inform better treatment decisions, and monitor response to therapy. The firm also offers a range of pre-clinical (animal imaging) reagents for use with microPET, microSPECT, and optical imaging systems. The company was founded by Christian P. Behrenbruch, Tove Olafsen, Anna M. Wu, and Robert E. Reiter in 2007 and is headquartered in Inglewood, CA.